The study aimed to assess the effectiveness and safety of combining nedaplatin and tegafur for patients with advanced esophageal cancer.
A total of 65 patients participated, with varying histories of chemotherapy; results showed a higher response rate (81.5%) in chemotherapy-naïve patients compared to those with previous treatment (44.4%).
Overall, the combined treatment was found to be effective and tolerable, although nausea and vomiting were common mild side effects.